Glenmark Pharmaceuticals announced results from a Phase 1 study that suggest similarity in pharmacokinetic, pharmacodynamic, safety and immunogenicity profiles between Glenmark's GBR 310 proposed biosimilar and reference product omalizumab, marketed in the U.S. under the brand name Xolair®...read more
Glenmark Pharmaceuticals Ltd dropped for a fifth straight session today. The stock is quoting at 529.5, down 1.08% on the day as on 13:29 IST on the NSE. The benchmark NIFTY is up around 0.57% on t...read more
